Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An Open Question: Is the A2A Adenosine Receptor a Novel Target for Alzheimer’s Disease Treatment?
Stefania Merighi, Tino Emanuele Poloni, Lucia Pelloni, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 16

Showing 16 citing articles:

Adenosine and Inflammation: Here, There and Everywhere
Silvia Pasquini, Chiara Contri, Pier Andrea Borea, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7685-7685
Open Access | Times Cited: 113
Alterations in the Processing of Platelet APP (Amyloid Beta Precursor Protein) in Alzheimer Disease: The Possible Nexus
Hayder M. Al‐kuraishy, Ghassan M. Sulaiman, Hamdoon A. Mohammed, et al.
Neuropsychopharmacology Reports (2025) Vol. 45, Iss. 1
Open Access | Times Cited: 3
Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets
Silvia Pasquini, Chiara Contri, Stefania Merighi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1219-1219
Open Access | Times Cited: 38
Caffeine for Prevention of Alzheimer’s Disease: Is the A2A Adenosine Receptor Its Target?
Stefania Merighi, Alessia Travagli, Manuela Nigro, et al.
Biomolecules (2023) Vol. 13, Iss. 6, pp. 967-967
Open Access | Times Cited: 16
Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral Aβ-Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study
Samantha L. Gardener, Stephanie R. Rainey‐Smith, Victor L. Villemagne, et al.
Frontiers in Aging Neuroscience (2021) Vol. 13
Open Access | Times Cited: 32
A2A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer’s Disease
Stefania Gessi, Tino Emanuele Poloni, G Negro, et al.
Cells (2021) Vol. 10, Iss. 9, pp. 2344-2344
Open Access | Times Cited: 29
A2A Adenosine Receptor Antagonists in Neurodegenerative Diseases
Stefania Merighi, Pier Andrea Borea, Katia Varani, et al.
Current Medicinal Chemistry (2021) Vol. 29, Iss. 24, pp. 4138-4151
Open Access | Times Cited: 28
Pathophysiological Role and Medicinal Chemistry of A2A Adenosine Receptor Antagonists in Alzheimer’s Disease
Stefania Merighi, Pier Andrea Borea, Katia Varani, et al.
Molecules (2022) Vol. 27, Iss. 9, pp. 2680-2680
Open Access | Times Cited: 21
Update on the recent development of allosteric modulators for adenosine receptors and their therapeutic applications
Silvia Pasquini, Chiara Contri, Martina Cappello, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 15
Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?
Stefania Merighi, Tino Emanuele Poloni, Anna Terrazzan, et al.
Cells (2021) Vol. 10, Iss. 5, pp. 1267-1267
Open Access | Times Cited: 19
A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists
Kenneth A. Jacobson, R. Rama Suresh, Paola Oliva
International review of neurobiology (2023), pp. 1-27
Open Access | Times Cited: 2
Molecular Integration in Adenosine Heteroreceptor Complexes Through Allosteric and De-Phosphorylation (STEP) Mechanisms and its Role in Brain Disease
Dasiel O. Borroto‐Escuela, Luca Ferraro, Kjell Fuxé
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 3
The adenosine A2A receptor is a therapeutic target in neurological, heart and oncogenic diseases
Rafael Franco, Alejandro Lillo, Gemma Navarro, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 9, pp. 791-800
Closed Access | Times Cited: 3
Susceptibility of GPCR Heteroreceptor Complexes to Neurotoxins. Relevance for Neurodegenerative and Psychiatric Disorders
Dasiel O. Borroto‐Escuela, Rasiel Beltran-Casanueva, Alexander López‐Salas, et al.
Springer eBooks (2022), pp. 2141-2150
Closed Access | Times Cited: 1
Dual Anta-Inhibitors Targeting Protein Kinase CK1δ and A2A Adenosine Receptor Useful in Neurodegenerative Disorders
Beatrice Francucci, Simone Angeloni, Diego Dal Ben, et al.
Molecules (2023) Vol. 28, Iss. 12, pp. 4762-4762
Open Access
Susceptibility of GPCR Heteroreceptor Complexes to Neurotoxins. Relevance for Neurodegenerative and Psychiatric Disorders
Dasiel O. Borroto‐Escuela, Rasiel Beltran-Casanueva, Alexander López‐Salas, et al.
Springer eBooks (2022), pp. 1-11
Closed Access
Page 1

Scroll to top